Journal of Shandong University (Health Sciences) ›› 2022, Vol. 60 ›› Issue (4): 91-98.doi: 10.6040/j.issn.1671-7554.0.2021.1451

Previous Articles    

Pharmacoeconomic evaluation of levosimendan and milrinone in the treatment of 711 patients with severe heart failure complicated with renal injury

DONG Xue1,2,3, ZHAO Xia4, CHENG Zijie5, HAN Yi4   

  1. 1. Centre for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China;
    2. NHC Key Lab of Health Economics and Policy Research (Shandong University), Jinan 250012, Shandong, China;
    3. Department of Education, The First Affiliated Hospital of Shandong First Medical University &
    Shandong Provincial Qianfoshan Hospital, Jinan 250014, Shandong, China;
    4. Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University &
    Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Jinan 250014, Shandong, China;
    5. Department of Clinical Pharmacy, School of Basic Medicine, China Pharmaceutical University, Nanjing 210009, Jiangsu, China
  • Published:2022-04-22

PDF (PC)

89

Abstract: Objective To investigate the cost-effectiveness differences between levosimendan and milrinone in treating severe heart failure complicated with normal, mild and moderate impaired renal function. Methods A total of 711 patients hospitalized in the Cardiology Department of Shandong Provincial Qianfoshan Hospital due to severe heart failure during Dec. 2016 and Sep. 2019 were enrolled. According to the renal function, the patients were divided into moderate renal injury group(n=299)and normal renal function or mild renal injury group(n=412), and then divided into levosimendan subgroup and milrinone subgroup. The information and clinical outcomes of patients 30 days after drug use were collected through the electronic medical record system and follow-up visits. With “obvious efficiency” with no adverse clinical events, and “efficiency” with no death within 30 days as effectiveness indexes, and the discount adjusted total hospitalization cost as the cost index, a decision tree analysis model was constructed, and cost-effectiveness analysis and one-way sensitivity analysis were performed. Results In the moderate renal injury group, with “obvious efficiency” as the effectiveness index, milrinone had absolute pharmacoeconomic advantages; with “efficiency” as the effectiveness index, each 1% more efficiency of levosimendan costed ￥4 562.64 more than that of milrinone. In the normal renal function or mild renal injury group, the total hospitalization cost of levosimendan was lower than that of milrinone, and each 1% increase in obvious efficiency of milrinone costed ￥400.89 more than that of levosimendan, and each 1% increase in efficiency of milrinone costed ￥1 751.16 more than that of levosimendan. The sensitivity analysis results were robust. Conclusion Based on real-world data, milrinone has an economic advantage over levosimendan in severe heart failure patients with moderate renal injury. For patients with normal renal function or mild renal injury, levosimendan has a moderate economic advantage over milrinone.

Key words: Severe heart failure, Levosimendan, Milrinone, Cost-effectiveness analysis, Decision tree model, Pharmacoeconomics

CLC Number: 

  • R956
[1] Bistola V, Arfaras-Melainis A, Polyzogopoulou E, et al. Inotropes in acute heart failure: from guidelines to practical use: therapeutic options and clinical practice [J]. Card Fail Rev, 2019, 5(3): 133-139.
[2] Chan CC, Lee KT, Ho WJ, et al. Levosimendan use in patients with acute heart failure and reduced ejection fraction with or without severe renal dysfunction in critical cardiac care units: a multi-institution database study [J]. Ann Intensive Care, 2021, 11(1): 27.
[3] 兰洪涛, 贾旭, 童洲杰,等. 无选择性152例成年慢性心力衰竭患者再入院的危险因素[J]. 山东大学学报(医学版), 2021, 59(4): 63-69. LAN Hongtao, JIA Xu, TONG Zhoujie, et al. Readmission prediction of 152 non-selective adult patients with chronic heart failure [J]. Jouranl of Shandong University(Health Sciences), 2021, 59(4): 63-69.
[4] 王华, 李莹莹, 柴坷, 等. 中国住院心力衰竭患者流行病学及治疗现状[J]. 中华心血管病杂志, 2019, 47(11): 865-874. WANG Hua, LI Yingying, CHAI Ke, et al. Contemporary epidemiology and treatment of hospitalized heart failure patients in real clinicalpractice in China [J]. Chinese Journal of Cardiology, 2019, 47(11): 865-874.
[5] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心力衰竭和心肌病杂志, 2018, 2(4): 196-225.
[6] Nandkeolyar S, Ryu R, Mohammad A, et al. A review of inotropes and inopressors for effective utilization in patients with acute decompensated heart failure [J]. J Cardiovasc Pharmacol, 2021, 78(3): 336-345.
[7] Tholén M, Ricksten SE, Lannemyr L. Effects of levosimendan on renal blood flow and glomerular filtration in patients with acute kidney injury after cardiac surgery: a double blind, randomized placebo-controlled study [J]. Crit Care, 2021, 25(1): 207.
[8] Cholley B, Levy B, Fellahi JL, et al. Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper [J]. Crit Care, 2019, 23(1): 385.
[9] 沈晓红. 比较左西孟旦与多巴酚丁胺治疗老年急性心力衰竭的效果及药物经济学分析[J]. 中国乡村医药, 2018, 25(24): 38-39.
[10] 曹俊强, 李彩霞, 赵习玲,等. 米力农与左西孟旦治疗难治性心力衰竭的效果对比[J]. 中国实用医刊, 2021, 48(3): 103-105. CAO Junqiang, LI Caixia, ZHAO Xiling, et al. Comparison on effect of milrinone versus levosimendan on refractory heart failure [J]. Chinese Journal of Practical Medicine, 2021, 48(3): 103-105.
[11] 汪佩, 姬新才. 米力农治疗心力衰竭的临床进展[J]. 世界最新医学信息文摘(连续型电子期刊), 2021, 21(10): 127-129. WANG Pei, JI Xincai. Clinical progress of milrinonein the treatment of heart failure [J]. World Latest Medicine Information(Electronic Version), 2021, 21(10): 127-129.
[12] 李志勇. 左西孟旦和米力农治疗慢性心衰急性发作的临床疗效对比分析[J]. 临床医药文献电子杂志, 2019, 6(41): 5, 7. LI Zhiyong. A comparative analysis of the clinical efficacy of levosimendan and milrinone in the treatment of acute episodes of chronic heart failure [J]. Electronic Journal of Clinical Medical Literature, 2019, 6(41): 5, 7.
[13] 修志贞. 左西孟旦与米力农治疗对重症顽固性心衰患者血清脑钠肽及尿酸水平的影响[J]. 世界最新医学信息文摘(连续型电子期刊), 2021, 21(14): 169-170.
[14] 胡学松, 冷利华. 左西孟旦与米力农注射液治疗老年失代偿性心力衰竭临床疗效的对比研究[J]. 实用心脑肺血管病杂志, 2017, 25(8): 78-81. HU Xuesong, LENG Lihua. Comparative study for clinical effect in treating elderly patients with decompensated heart failure between levosimendan and milrinone injection [J]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease, 2017, 25(8): 78-81.
[15] Papp Z, Agostoni P, Alvarez J, et al. Levosimendan efficacy and safety: 20 years of SIMDAX in clinical use [J]. J Cardiovasc Pharmacol, 2020, 76(1): 4-22.
[16] Landoni G, Lomivorotov VV, Alvaro G, et al. Levosimendan for hemodynamic support after cardiac surgery[J]. N Engl J Med, 2017, 376(21): 2021-2031.
[17] Pisano A, Monti G, Landoni G. Levosimendan: new indications and evidence for reduction in perioperative mortality?[J]. Curr Opin Anaesthesiol, 2016, 29(4): 454-461.
[18] 王治, 李益民, 严雪娇, 等. 139例慢性心力衰竭患者肾功能及预后分析[J]. 中国心血管病研究, 2017, 15(8): 706-709. WANG Zhi, LI Yimin,YAN Xuejiao, et al. Analysis of renal function and its effect on clinical prognosis in 139 patients with heart failure [J]. Chinese Journal of Cardiovaseftlar Research, 2017, 15(8): 706-709.
[19] Gist KM, Goldstein SL, Joy MS, et al. Milrinone dosing issues in critically ill children with kidney injury: a review [J]. J Cardiovasc Pharmacol, 2016, 67(2): 175-181.
[20] Zima E, Farmakis D, Pollesello P, et al. Differential effects of inotropes and inodilators on renal function in acute cardiac care [J]. Eur Heart J Suppl, 2020, 22(Suppl D): D12-D19.
[21] 田艳平, 崔向丽, 刘丽宏,等. 基于决策树模型对我国6种保肝药物治疗药物性肝损伤的成本-效果分析[J]. 中国药物应用与监测, 2018, 15(3): 131-135. TIAN Yanping, CUI Xiangli, LIU Lihong, et al. Cost-effectiveness analysis of the six kinds of hepatoprotective drugs in the treatment of drug-induced liver injury in China based on the decision tree model [J]. Chinese Journal of Drug Application and Monitoring, 2018, 15(3): 131-135.
[22] 李洪超. 基于文献的药物经济学评价: 方法和挑战[J]. 药学与临床研究, 2016, 24(2): 188-191.
[23] 张楠, 石学峰, 吴晶. 增量成本效果比在卫生技术评估中的应用[J]. 中国卫生政策研究, 2012, 5(2): 64-68. ZHANG Nan, SHI Xuefeng, WU Jing. The application of incremental cost-effectiveness ratio to health technology assessment[J]. Chinese Journal of Health Policy, 2012, 5(2): 64-68.
[24] 刘霄岩. 米力农治疗难治性心力衰竭80例临床观察[J]. 山东大学学报(医学版), 2014, 52(z2): 61, 63.
[25] Papp Z, Agostoni P, Alvarez J, et al. Levosimendan efficacy and safety: 20 years of SIMDAX in Clinical Use [J]. Card Fail Rev, 2020, 6: e19. doi: 10.15420/cfr.2020.03.
[26] Sangalli F, Bellani G, Affronti A, et al. Levosimendan to facilitate weaning from cardiorespiratory support in critically ill patients: current evidence and future directions [J]. Minerva Anestesiol, 2020, 86(6): 645-651.
[1] XU Tianyi, WU Ping, WANG Ailing, CHEN Liping. Clinical effect of milrinone atomization inhalation on treating severe pneumonia complicated with heart failure of neonates and infants [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(7): 88-90.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] XU Ge, LI Qing, ZHANG Cancan, TIAN Yongjie. Expressions and clinical significance of PARP-1 and HIF-1α in adenomyosis tissues and primary cells[J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 55 -61 .
[2] CHEN Zhaobo, FANG Min, XUE Haoran, LIU Chunyan. Deubiquitinase USP35 promotes the cells migration and invasion of non-small cell lung cancer[J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 30 -37 .
[3] SHAO Na, YIN Hao, LI Yaran, ZHANG Baokun, HUANG Weiwei, LU Shanshan, TANG Jiyou. Study on the mechanism of Suvorexant treatment ameliorates learning and memory impairment in chronic sleep deprivation mice model[J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 17 -23 .
[4] ZHAO Tingting, QI Yana, ZHANG Ying, YUAN Bing, HAN Mingyong. Mouse breast cancer induces changes of the microenvironment in pre-metastatic lung tissue[J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 24 -29 .
[5] YANG Congpin, LUO Zhuoye, XU Xiuhua, LI Aimin, HAO Guimin. Reproductive choices and pressure in 3,512 women of childbearing age in a hospital in Hebei Province[J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 62 -67 .
[6] ZHAO Hailong, WANG Hao, FANG Yuqing, MAO Fei, ZHAO Zhangning, TIAN Xiangqi, XU Xinrong, WANG Min, LI Xiuhua. Efficacy of additional idebenone in the treatment of 34 patients with Parkinsons disease with depression[J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 38 -44 .
[7] LI Honghao, YU Jing, CHEN Yali, GUO Shougang. Evaluation of CD4+CD25+FoxP3+ regulatory T cells and FoxP3 mRNA expression in 20 NMOSD patients[J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 50 -54 .
[8] LIU Liwen, MA Jun, LI Peizheng, ZHANG Xiufang, LIU Yiming. Caregiver burden and influencing factors of 128 patients with Parkinsons disease[J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 45 -49 .
[9] SUN Jiye, WANG Ziou, SUN Xiaowei, LI Hongtao. Effects of traditional Chinese medicine fumigation combined with extracorporeal shock wave therapy on 72 cases of femoroacetabular impingement syndrome and serum inflammatory factor[J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 76 -81 .
[10] YUAN Hongtao, JI Congshan, KANG Bing, QIN Songnan, YU Xinxin, GAO Lin, WANG Ximing. Diagnostic value of CT radiomics nomogram for adrenal lipid-poor adenoma and nodular hyperplasia[J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 68 -75 .
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd